Delivering precision oncology to patients with cancer
With the increasing use of genomic profiling for diagnosis and therapy guidance in many
tumor types, precision oncology is rapidly reshaping cancer care. However, the current …
tumor types, precision oncology is rapidly reshaping cancer care. However, the current …
Liquid biopsy enters the clinic—implementation issues and future challenges
M Ignatiadis, GW Sledge, SS Jeffrey - Nature reviews Clinical oncology, 2021 - nature.com
Historically, studies of disseminated tumour cells in bone marrow and circulating tumour
cells in peripheral blood have provided crucial insights into cancer biology and the …
cells in peripheral blood have provided crucial insights into cancer biology and the …
Structure-based classification predicts drug response in EGFR-mutant NSCLC
Epidermal growth factor receptor (EGFR) mutations typically occur in exons 18–21 and are
established driver mutations in non-small cell lung cancer (NSCLC),–. Targeted therapies …
established driver mutations in non-small cell lung cancer (NSCLC),–. Targeted therapies …
[PDF][PDF] The challenges of tumor mutational burden as an immunotherapy biomarker
DL Jardim, A Goodman, D de Melo Gagliato… - Cancer cell, 2021 - cell.com
Tumor mutational burden (TMB) reflects cancer mutation quantity. Mutations are processed
to neo-antigens and presented by major histocompatibility complex (MHC) proteins to T …
to neo-antigens and presented by major histocompatibility complex (MHC) proteins to T …
Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study
Background Systemic therapies for metastatic biliary tract cancers are few, and patients
have a median overall survival of less than 1 year. MyPathway evaluates the activity of US …
have a median overall survival of less than 1 year. MyPathway evaluates the activity of US …
[Retracted] A Comprehensive Review of Performance of Next‐Generation Sequencing Platforms
MT Pervez, MJ Hasnain, SH Abbas… - BioMed Research …, 2022 - Wiley Online Library
Background. Next‐generation sequencing methods have been developed and proposed to
investigate any query in genomics or clinical activity involving DNA. Technical advancement …
investigate any query in genomics or clinical activity involving DNA. Technical advancement …
Tumor mutational burden as a predictive biomarker in solid tumors
Tumor mutational burden (TMB), defined as the number of somatic mutations per megabase
of interrogated genomic sequence, varies across malignancies. Panel sequencing–based …
of interrogated genomic sequence, varies across malignancies. Panel sequencing–based …
Overcoming therapy resistance in EGFR-mutant lung cancer
Tyrosine kinase inhibitors (TKIs) have dramatically changed the clinical prospects of patients
with non-small cell lung cancer harboring epidermal growth factor receptor (EGFR) …
with non-small cell lung cancer harboring epidermal growth factor receptor (EGFR) …
Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group
Next-generation sequencing (NGS) allows sequencing of a high number of nucleotides in a
short time frame at an affordable cost. While this technology has been widely implemented …
short time frame at an affordable cost. While this technology has been widely implemented …
Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration
PURPOSE BRCA1 or BRCA2 (BRCA) alterations are common in men with metastatic
castration-resistant prostate cancer (mCRPC) and may confer sensitivity to poly (ADP …
castration-resistant prostate cancer (mCRPC) and may confer sensitivity to poly (ADP …